Search

1 to 10 of 202
Sort by

Library Entry
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article identifying appropriate early efficacy metrics predictive of overall survival for immunotherapy trials. Authors: Meihua Wang, Cong Chen , Thomas Jemielita , James Anderson , Xiaoyun (Nicole) Li , Chen...


Library Entry
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small c

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article describing a phase Ib clinical trial evaluating treatment with BI1361849 combined with local radiation in 26 stage IV NSCLC patients with partial response (PR)/stable disease (SD) after standard first-line therapy...


Library Entry
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article seeking to improve Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC). Results show some features were associated with favorable response to nivolumab for AGC....


Library Entry
FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article illustrating that FLT PET uptake was significantly predictive of progression-free survival and the occurrence of adverse events relating to thyroid function. The results suggest FLT PET imaging has potential as a...


Library Entry
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article providing key clinical data in patients with solid epithelial tumors following treatment with IV enadenotucirev monotherapy and supports further investigation of enadenotucirev in combination with other...


Library Entry
Advances in Cancer Immunotherapy™ Webinar Series: Updates from the Field - Clinical Updates from SITC 2018

This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. More specifically, program organizers Christian M. Capitini, MD, and Zachary S. Morris,...



Library Entry
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article the PARP inhibitor olaparib was combined with durvalumab to treat mCRPC, regardless of patients’ mutational status. Authors: Fatima Karzai , David VanderWeele , Ravi A. Madan , Helen Owens , Lisa M. Cordes ...


Library Entry
Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Published in the Journal for ImmunoTherapy of Cancer (JITC), is an update on long-term survival results from two single-arm, phase II adjuvant trials (Trial 3 and Trial 5) with the focus on treatment beyond recurrence of the disease. Authors: Jacek Mackiewicz , Tomasz Burzykowski , Dariusz...